Clinical Efficacy of Osimertinib in Patients with Advanced Non-Small Cell Lung Cancer and Its Effect on Serum CEA and VEGF Expression.

IF 1.1 4区工程技术 Q3 MATERIALS SCIENCE, CHARACTERIZATION & TESTING

Archives of Mechanics Pub Date : 2022-05-25 eCollection Date: 2022-01-01 DOI:10.1155/2022/3032087

Huanyuan Wang, Xiangwu Zhou, Zhaozhen Wang, Tianzhu Lu, Baoliang Li, Sicong Jiang

{"title":"Clinical Efficacy of Osimertinib in Patients with Advanced Non-Small Cell Lung Cancer and Its Effect on Serum CEA and VEGF Expression.","authors":"Huanyuan Wang, Xiangwu Zhou, Zhaozhen Wang, Tianzhu Lu, Baoliang Li, Sicong Jiang","doi":"10.1155/2022/3032087","DOIUrl":null,"url":null,"abstract":"Objective: To assess the clinical efficacy of osimertinib in patients with advanced non-small cell lung cancer and its effect on serum carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) expression.Methods: Between July 2018 and January 2020, 80 patients with advanced non-small cell lung cancer were assessed for eligibility and recruited. The patients were assigned at a ratio of 1 : 1 to receive either the PC regimen (pemetrexed + cisplatin) (conventional group) or osimertinib (experimental group). The primary endpoint was the clinical efficacy, and the secondary endpoints were the adverse events, expression of serum CEA and VEGF, and 2-year survival.Results: Osimertinib was associated with a significantly higher response rate and disease control rate versus pemetrexed plus cisplatin (P < 0.05). Osimertinib resulted in a significantly lower incidence of adverse events versus the PC regimen (P < 0.05). Patients given osimertinib had significantly lower levels of CEA and VEGF versus those given pemetrexed plus cisplatin (P < 0.05). Osimertinib was associated with a significantly higher 1-year and 2-year survival rate versus pemetrexed plus cisplatin.Conclusion: Osimertinib could inhibit the expression of serum CEA and VEGF in patients with advanced non-small cell lung cancer and reduce the adverse events with significant efficacy, so it is worthy of clinical promotion and application.","PeriodicalId":8280,"journal":{"name":"Archives of Mechanics","volume":"70 1","pages":"3032087"},"PeriodicalIF":1.1000,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159882/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Mechanics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2022/3032087","RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MATERIALS SCIENCE, CHARACTERIZATION & TESTING","Score":null,"Total":0}

引用次数: 1

Abstract

Objective: To assess the clinical efficacy of osimertinib in patients with advanced non-small cell lung cancer and its effect on serum carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) expression.

Methods: Between July 2018 and January 2020, 80 patients with advanced non-small cell lung cancer were assessed for eligibility and recruited. The patients were assigned at a ratio of 1 : 1 to receive either the PC regimen (pemetrexed + cisplatin) (conventional group) or osimertinib (experimental group). The primary endpoint was the clinical efficacy, and the secondary endpoints were the adverse events, expression of serum CEA and VEGF, and 2-year survival.

Results: Osimertinib was associated with a significantly higher response rate and disease control rate versus pemetrexed plus cisplatin (P < 0.05). Osimertinib resulted in a significantly lower incidence of adverse events versus the PC regimen (P < 0.05). Patients given osimertinib had significantly lower levels of CEA and VEGF versus those given pemetrexed plus cisplatin (P < 0.05). Osimertinib was associated with a significantly higher 1-year and 2-year survival rate versus pemetrexed plus cisplatin.

Conclusion: Osimertinib could inhibit the expression of serum CEA and VEGF in patients with advanced non-small cell lung cancer and reduce the adverse events with significant efficacy, so it is worthy of clinical promotion and application.

查看原文本刊更多论文

奥希替尼对晚期非小细胞肺癌患者的临床疗效及其对血清 CEA 和血管内皮生长因子表达的影响

目的评估奥希替尼对晚期非小细胞肺癌患者的临床疗效及其对血清癌胚抗原（CEA）和血管内皮生长因子（VEGF）表达的影响：2018年7月至2020年1月，对80名晚期非小细胞肺癌患者进行资格评估并招募。患者按 1 ：1的比例分配，接受PC方案（培美曲塞+顺铂）（常规组）或奥西替尼（实验组）治疗。主要终点是临床疗效，次要终点是不良事件、血清CEA和VEGF的表达以及2年生存率：与培美曲塞加顺铂相比，奥希替尼的应答率和疾病控制率明显更高（P < 0.05）。与 PC 方案相比，奥希替尼的不良反应发生率明显降低（P < 0.05）。与培美曲塞加顺铂方案相比，奥希替尼治疗患者的癌胚抗原（CEA）和血管内皮生长因子（VEGF）水平明显降低（P < 0.05）。与培美曲塞加顺铂相比，奥希替尼的1年和2年生存率明显更高：奥希替尼可抑制晚期非小细胞肺癌患者血清CEA和VEGF的表达，减少不良反应，疗效显著，值得临床推广应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archives of Mechanics 工程技术-材料科学：表征与测试

CiteScore

1.40

自引率

12.50%

发文量

审稿时长

>12 weeks

期刊介绍： Archives of Mechanics provides a forum for original research on mechanics of solids, fluids and discrete systems, including the development of mathematical methods for solving mechanical problems. The journal encompasses all aspects of the field, with the emphasis placed on: -mechanics of materials: elasticity, plasticity, time-dependent phenomena, phase transformation, damage, fracture; physical and experimental foundations, micromechanics, thermodynamics, instabilities; -methods and problems in continuum mechanics: general theory and novel applications, thermomechanics, structural analysis, porous media, contact problems; -dynamics of material systems; -fluid flows and interactions with solids. Papers published in the Archives should contain original contributions dealing with theoretical, experimental, or numerical aspects of mechanical problems listed above. The journal publishes also current announcements and information about important scientific events of possible interest to its readers, like conferences, congresses, symposia, work-shops, courses, etc. Occasionally, special issues of the journal may be devoted to publication of all or selected papers presented at international conferences or other scientific meetings. However, all papers intended for such an issue are subjected to the usual reviewing and acceptance procedure.